Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,429 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Corticoids Clear all
Active, not recruiting Phase 3 Interventional

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

NCT03020030
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2034
U.S. locations
7
States / cities
Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 6:09 PM EDT
Suspended Phase 2 Interventional

Novel Intervention for Chronic Complex TBI in OEF/OIF/OND Veterans

NCT05671692
View directory record Official record
Conditions
Traumatic Brain Injury, TBI
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Christine Marx, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 6:09 PM EDT
Terminated Not applicable Interventional Results available

Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma

NCT01881412
View directory record Official record
Conditions
Asthma
Interventions
fluticasone, Standard Asthma Discharge Instructions
Drug · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
3 Years to 12 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 21, 2026, 6:09 PM EDT
Terminated Not applicable Interventional Results available

Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):

NCT02027272
View directory record Official record
Conditions
Eclampsia
Interventions
Dexamethasone
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

NCT02614612
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Dolutegravir and Prednisone

NCT01425099
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir, Prednisone
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Not applicable Interventional

Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors

NCT02200133
View directory record Official record
Conditions
Adult Hematopoietic Cell Transplant (HCT) Survivors 1-2 Yrs Post Most Recent HCT
Interventions
Individualized Survivorship Care Plan (SCP)
Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Scottsdale, Arizona • Gainesville, Florida • Maywood, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 21, 2026, 6:09 PM EDT
Withdrawn Not applicable Interventional

Preoperative Corticosteroid Epidural Injection and Lumbar Decompression Surgery Outcomes

NCT03543033
View directory record Official record
Conditions
Lumbar Radiculopathy
Interventions
Corticosteroid injection
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
30 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

NCT02883049
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
Interventions
Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
5,949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 21, 2026, 6:09 PM EDT
Terminated Phase 2 Interventional Results available

Investigation of Corticosteroid Versus Placebo Injection in Patients With Syndesmotic Ligament Injury or High Ankle Sprain

NCT02892500
View directory record Official record
Conditions
Ankle Injuries
Interventions
bupivacaine hydrochloride and betamethasone sodium phosphate, bupivacaine hydrochloride
Drug
Lead sponsor
Sanford Health
Other
Eligibility
16 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

NCT01068600
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
54
States / cities
Anniston, Alabama • Jasper, Alabama • Glendale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 21, 2026, 6:09 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 21, 2026, 6:09 PM EDT
Recruiting Phase 2 Interventional

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

NCT07407647
View directory record Official record
Conditions
Anal Carcinoma, Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Biospecimen Collection, Prasterone, Survey Administration
Procedure · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

NCT01903993
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Docetaxel, Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
29
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Loma Linda, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 21, 2026, 6:09 PM EDT
Active, not recruiting Phase 4 Interventional

Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing

NCT07281014
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Spironolactone 25mg, Aldosterone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery

NCT05023304
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical prednisolone acetate
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 21, 2026, 6:09 PM EDT
Recruiting Phase 2 Interventional

Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE

NCT06705387
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Fluticasone
Biological · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 25 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

NCT00310791
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA)
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 30 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 21, 2026, 6:09 PM EDT
Recruiting Phase 4 Interventional

ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)

NCT07448610
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Onasemnogene Abeparvovec-brve
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 6:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

NCT03817320
View directory record Official record
Conditions
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Interventions
Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study

NCT04396990
View directory record Official record
Conditions
Refractive Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Not applicable Interventional Results available

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

NCT00096135
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
18 Months to 29 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
135
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 21, 2026, 6:09 PM EDT
Terminated Not applicable Interventional Results available

Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

NCT01156480
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
hydrocortisone, placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
0 Days to 6 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 21, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02105974
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 21, 2026, 6:09 PM EDT